David Rosenthal: belief

Transcript context

…Thirty-two years after Lotte and her team started this research. Right. If anything, we think of this company as like, oh, it's the GLP-1 company, it's the weight loss drug company. No. For a hundred years, it was the Diabetes and the Insulin company. But it's clear at this point now that no, this is now a GLP-1 company. That grew naturally out of the Diabetes, the Insulin research, Lotte's work, and in this organic fashion that is so different than the rest of the pharma industry. But the net result of this now is that yes, Insulin is still a large business within Novo Nordisk, but it is a GLP-1 company. When Wegovy finally launches in the US in 2021 as the official FDA sanctioned weight loss version of Semaglutide, it gets the same number of prescriptions written for it by doctors in the first slightly over one month than Saxenda had in its entire drug lifetime. People were already "misusing" Ozempic for weight loss before this. Ozempic supply was fully exhausted, and then now Wegovy supply fully exhausted. In February of 2021, after the clinical trial finishes on Semaglutide for weight loss for Wegovy to hit the market in the US, the New York Times runs a story and just calls it a game changer. They say, for the first time, a drug has been shown to be so effective against obesity that patients may dodge many of its worst consequences, including Diabetes. With the biggest megaphone you could possibly point at people, they're being told that this thing freaking works and it's a miracle drug.…

Stored transcript either side of the excerpt. The highlighted words are the published quote; the surrounding text is unedited source, never generated.